TCT-416 Drug eluting balloon: a real world three centers experience
نویسندگان
چکیده
منابع مشابه
Drug Eluting Balloon
Since the first percutaneous transluminal coronary angioplasty (PTCA) performed by Andreas Gruntzig in 1977 the technology has evolved significantly. Progress of PTCA has seen the development of many devices, some of which are still in use and many others that have fallen in disuse. The main limitation of the plain old balloon angioplasty (POBA) was the problem of elastic vascular recoil causin...
متن کاملA three-dimensional mathematical model for drug delivery from drug-eluting stents
Current drug-eluting stent (DES) technology is not optimized with regard to the pharmacokinetics of drug release, more research on the <span style="font-size: 12pt; color: #000000; font-style: normal; ...
متن کاملTreatment of coronary in-stent restenosis with drug-eluting balloon catheter: real-world outcome and literature review.
Dear Editor, Currently, coronary stent implantation is employed in approximately 90% of percutaneous coronary intervention (PCI) cases. Despite the use of drug-eluting stents (DES), coronary in-stent restenosis (ISR) remains an Achilles’ heel of PCI and can occur in about 10% of patients in the real-world population.1,2 We explored the effi cacy of a novel approach using drug-eluting balloon (D...
متن کاملEfficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
INTRODUCTION In spite of improving results, the treatment of in-stent restenosis (ISR) of bare-metal stents (BMS), and particularly drug-eluting stents (DES), is a challenging clinical problem. There are promising but limited follow-up data concerning drug-eluting balloons in the treatment of BMS and DES restenosis. The goal of this real-world registry was to assess the long-term safety and eff...
متن کاملAssociations Between Target Lesion Restenosis and Drug-Eluting Balloon Use
Percutaneous coronary interventions (PCIs) with drug-eluting balloons (DEBs) have emerged as an adjunctive treatment for in-stent restenosis (ISR) lesions. However, recurrent restenosis still occurs following DEB use. Our study aimed to identify the associations of target lesion restenosis following DEB use over a 1-year clinical follow-up.Between November 2011 and May 2014, 246 patients were d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2015
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2015.08.430